CBD-Tacrolimus interaction study completed: key dosing insights for transplant recipients
NCT ID NCT05490511
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how cannabidiol (CBD) interacts with tacrolimus, a drug used to prevent organ rejection in transplant patients. Researchers wanted to understand how to adjust doses for better health outcomes. The study involved 57 healthy adults and those with chronic kidney disease, measuring drug levels and immune responses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY DISEASE, CHRONIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IU Health University Hospital
Indianapolis, Indiana, 46202, United States